The bioequivalence problem is of practical importance because the approval of most generic drugs in the United States and the European Community (EC) requires the establishment of bioequivalence between the name brand drug and the proposed generic version. The problem is theoretically interesting because it has been recognized as one for which the desired inference, instead of the usual signi cant di erence, is practical equivalence. The concept of intersection-union tests will be shown to clarify, simplify, and unify bioequivalence testing. A test more powerful than the one currently speci ed by the FDA and EC guidelines will be derived. The claim that the bioequivalence problem de ned in terms of the ratio of parameters is more di cult than the problem de ned in terms of the di erence of parameters will be refuted. The misconception that size-bioequivalence tests generally correspond to 100(1?2 )% con dence sets will be shown to lead to incorrect statistical practices, and should be abandoned. Techniques for constructing 100(1? )% con dence sets that correspond to size-bioequivalence tests will be described. Finally, multiparameter bioequivalence problems will be discussed.
costly clinical trials to demonstrate the safety and e cacy of the generic product. Yet, this bioequivalence must be demonstrated in a statistically sound way to protect the consumer from ine ective or unsafe drugs.
These concentration by time measurements are connected with a polygonal curve and several variables are measured. The common measurements are AUC (Area Under Curve), C max (maximum concentration), and T max (time until maximum concentration). The two drugs are bioequivalent if the population means of AUC and C max are su ciently close. Descriptive statistics for T max are usually provided, but formal tests are not required.
For example, let T denote the population mean AUC for the generic (Test) drug and R denote the population mean AUC for the brand-name (Reference) drug. To demonstrate bioequivalence, the following hypotheses are tested:
H 
The values L and U are standards set by regulatory agencies that de ne how \close" the drugs must be to be declared bioequivalent. Currently, both the United States Food and Drug Administration (1992) and the European Community uses U = 1:25 and L = :80 = 1=1:25 for AUC. For C max , the United States again uses U = 1:25 and L = :80, but Europe uses the less restrictive limits U = 1:43 and L = :70 = 1=1:43 (Hauck et al. (1995) ). Note that these limits for AUC and C max are symmetric about one in the ratio scale. Often, logarithms are taken and the hypotheses (1) are stated as In a hypothesis test of (1) or (2), the Type I error rate is the probability of declaring the drugs to be bioequivalent, when in fact they are not. By setting up the hypotheses as in (1) or (2) and controlling the Type I error rate at a speci ed small value, say, = :05, the consumer's risk is being controlled. That (1) or (2) is the proper formulation in problems like these was recognized early on by some authors. For example, Lehmann (1959, p. 88) , not speci cally discussing bioequivalence, says, \One then sets up the (null) hypothesis that the parameter] does not lie within the required limits so that an error of the rst kind consists in declaring the parameter] to be satisfactory when in fact it is not." But not until Schuirmann (1981 Schuirmann ( , 1987 , Westlake (1981) and Anderson and Hauck (1983) were hypotheses correctly formulated as in (1) or (2) in bioequivalence problems.
Despite the fact that bioequivalence testing problems are now correctly formulated as (1) or (2), many inappropriate statistical procedures are still used in this area. Tests that claim to have a speci ed size , but are either liberal or conservative, are used. Liberal tests compromise the consumer's safety, and conservative tests put an undo burden on the generic drug manufacturer. Tests are often de ned in terms of con dence intervals in statistically unsound ways. These tests, again, do not properly control the consumer's risk.
In this paper, we will describe current bioequivalence tests that have incorrect error rates. We will o er new tests that correctly control the consumer's risk. In several cases, the tests we propose are uniformly more powerful than the existing tests while still controlling the Type I error rate at the speci ed rate . We will examine and criticize the current practice of de ning tests in terms of 100(1 ? 2 )% con dence sets. We will show that this only works in special cases and gives poor results in other cases. We will discuss how properly to construct 100(1? )% con dence sets that correspond to size-tests. And we will discuss how our methods can be applied to complicated, multiparameter bioequivalence problems that have received only slight attention in the literature. The intersection-union method of testing will be found to be very useful in understanding and constructing bioequivalence tests. Section 2 provides a more detailed outline to our discussions.
Hypotheses such as (1) and (2) that specify only that population means should be close are called average bioequivalence hypotheses. Hypotheses that state that the whole distribution of bioavailabilities is the same for the test and reference populations are called population bioequivalence hypotheses. If a parametric form of these populations is assumed, then hypotheses such as (25) that specify that all population parameters, e.g., variances as well as means, should be close are population bioequivalence hypotheses. Sometimes bioequivalence is de ned in terms of parameters that more directly measure equivalence of response within an individual. Good introductions to individual bioequivalence are given by Anderson and Hauck (1990) , Hauck and Anderson (1992) , Sheiner (1992) , Schall and Luus (1993) , and Anderson (1993) . Although we do not explicitly consider individual bioequivalence in this paper, many of the concepts and techniques we describe should be applicable in that area also.
In this paper, our discussion will be entirely in terms of bioequivalence testing. But our comments and techniques apply to other problems, such as in quality assurance, in which the aim is to show that two parameters are close or that a parameter is between two speci cation limits. Because of this wider applicability, the methods we will discuss might more properly be referred to as equivalence tests and equivalence con dence intervals.
Tests, Con dence Sets and Curiosities
Various experimental designs are used to gather data for bioequivalence trials. describe parallel designs (two independent samples), and two-period and multiperiod crossover designs. The issues we discuss apply to all these di erent designs. For brevity, we will discuss only the simple parallel design and two period crossover design.
Di erence hypotheses
It is customary to employ lognormal models in bioequivalence studies of AUC and C max . See Section 2.2 for rationales for this model. Let X denote a lognormal measurement from the test drug in the original scale, and let X = log(X ). Similarly, let Y denote an original measurement and Y = log(Y ) for the reference drug. Let ( T ; 2 ) denote the lognormal parameters for X and ( R ; 2 ) denote the lognormal parameters for Y . Then the test and reference drug means are T = e T + 2 =2 and R = e R + 2 =2 , respectively. Therefore, the condition
(3) where L = log( L ) and U = log( U ) are known constants. Thus, the hypothesis to be tested in this lognormal model can be stated as either (1) or (2). Usually the hypotheses are stated as (2) and the test is based on log transformed data that is normally distributed with means T and R and common variance 2 . The equivalence of (1) and (2) is dependent on the assumption of equal variances. On the other hand, if T and R represent the medians of X and Y and T = log( T ) and R = log( R ), then T and R are the medians of X and Y , respectively. So, in terms of medians, (1) and (2) are always equivalent, and the analysis can be carried out in either the original or log transformed scale. But, bioequivalence is almost always de ned in terms of means rather than medians. Westlake (1981) and Schuirmann (1981) proposed what has become the standard test of (2). It is called the \two one-sided tests" (TOST). The TOST has this general form. Let D be an estimate of T ? R that has a normal distribution with mean T ? R and variance 
The TOST tests (2) 
where t ;r is the upper 100 percentile of a Student's t distribution with r degrees of freedom. For testing (2), all the tests we will discuss are functions of (D; SE(D)). The distribution of (D; SE(D)) is determined by the parameter ( T ; R ; 2 D ).
In the simple parallel design, let X 1 ; : : :; X m denote the independent lognormal( T ; 2 ) measurements on m subjects from the test drug in the original scale, and let X 1 ; : : :; X m denote the logarithms of these measurements. Similarly, let Y 1 ; : : :; Y n and Y 1 ; : : :; Y n denote the original measurements (lognormal( R ; 2 )) and logarithms for an independent sample of n subjects on the reference drug. If X denotes the sample mean of X 1 ; : : :; X m , Y denotes the sample mean of Y 1 ; : : :; Y n , and S 2 denotes the pooled estimate of 2 In bioequivalence studies, much more common than simple parallel designs are twoperiod, crossover designs. In a two-period, crossover design, a group of m subjects (Sequence 1) receives the reference drug and observations on the pharmacokinetic response are made. After a washout period to remove any carryover e ect, this group receives the test drug and observations are again made. A second group of n subjects (Sequence 2) receives the drugs in the opposite order. After log transformation, the response of the kth subject in the jth period of the ith sequence is modeled as Y ijk = + S ik + P j + F (i;j) + ijk ;
where is the overall mean; P j is the xed e ect of period j; F (i;j) is the xed e ect of the formulation administered in period j of sequence i, that is, F (1;1) = F (2;2) = F R and F (1;2) = F (2;1) = F T ; S ik is the random e ect of subject k in sequence i; and ijk is the random error. It is assumed that P 1 + P 2 = F T + F R = 0. The S ik s and the ijk s are all independent normal random variables with mean 0. The size of the TOST is exactly equal to , even though P(reject H 0 ) < for every ( T ; R ; 2 D ) in the null hypothesis. The supremum value of is attained in the limit as T ? R = L (or U ) and 2 D ! 0. Both the FDA bioequivalence guideline (FDA, 1992) and the European Community guideline (EC-GCP, 1993) specify that bioequivalence be established using a 5% TOST. The TOST is unusual in that two size-tests are combined to form a size-test. Often, when multiple tests are combined, some adjustment must be made to the sizes of the individual tests to achieve an overall size-test. Why this is not necessary for the TOST is best understood through the theory of intersection-union tests (IUTs), which we describe in Section 3. In Sections 4.1 and 4.2 we will show that the IUT theory is useful for understanding the TOST. Also, the IUT theory can guide the construction of tests for (2) that have the same size-as the TOST but are uniformly more powerful than the TOST.
Ratio hypotheses
Sometimes, a normal model should be used. In this model, the original measurements are normally distributed with means T and R . This model is di erent from the lognormal model in that now the hypothesis to be tested concerns the ratio of the means of these normal observations. That is, we wish to test (1). This problem has received less attention than (2). Dealing with the ratio T = R has been perceived as more di cult than dealing with the di erence T ? R .
For AUC and C max , the FDA (1992) strongly recommends logarithmically transforming the data and testing the hypotheses (2). They o er three rationales for their recommendation. Based on these, the FDA (1992, p. 7) states, Based on the arguments in the preceding section, the Division of Bioequivalence recommends that the pharmacokinetic parameters AUC and C max be log transformed. Firms are not encouraged to test for normality of data distribution after log transformation, nor should they employ normality of data distribution as a justi cation for carrying out the statistical analysis on the original scale. The emphasis is ours.
The FDA's three rationales for log transformation are labeled Clinical, Pharmacokinetic, and Statistical. The Clinical Rationale is that the real interest is in the ratio T = R rather than the di erence T ? R . But, the link between this fact (which we certainly do not dispute) and the log transformation of the data is based on statistical considerations. It is that a linear statistical model can be used for the transformed data to make inferences about the di erence T ? R . These inferences then can be restated in terms of T = R .
Thus, the justi cation of the log transformations seems to be based mainly on the perceived di culty in dealing with the ratio T = R , rather than the di erence T ? R . If appropriate statistical procedures can be used to make inferences about the ratio T = R directly, then there seems to be no need for a log transformation. The Pharmacokinetic Rationale is based on multiplicative compartmental models of Westlake (1973 Westlake ( , 1988 . The multiplicative model is changed to a linear model by the log transformation. Part of the Statistical Rationale is that, in the original scale, much bioequivalence data is skewed and appears more lognormal than normal. We agree that these two considerations suggest that the rst method of analysis to be considered in bioequivalence studies is on the log transformed data, and, in most cases, this analysis will be appropriate.
The Statistical Rationale consists of the previous lognormal justi cation and two more points. The rst is that, Standard parametric methods are ill-suited to making inferences about the ratio of two averages, though some valid methods do exist. Log transformation changes the problem to one of making inferences about the di erence (on the log scale) of the two averages, for which the standard methods are well suited. The second is that the small sample sizes used in typical bioequivalence studies (20 to 30) will produce tests for normality that have fairly low power in either the original or log scale. The FDA recommends that no check of normality be made on the log transformed data. But, if a low-power normality test rejects the hypothesis of normality for the log transformed data, then surely some caution is warranted in the use of procedures that assume normality. In this case, tests such as the TOST, based on the Student's t distribution, are inappropriate. If normality of the log transformed data is rejected and the original data appear more normal than the log transformed data, then procedures that assume normality of the original data would seem more appropriate. In Section 4.3, we show that Sasabuchi (1980 Sasabuchi ( ,1988a described the size-likelihood ratio test for (1). It is a simple test based on the Student's t distribution. So the FDA's statement about ill-suited standard parametric procedures seems unfounded. We also show that the tests commonly used are liberal and have size greater than the nominal value of . Furthermore, we show that the IUT method can be used in this problem, also, to construct size-tests that are uniformly more powerful than the likelihood ratio test. Thus, the FDA's avoidance of (1) because of statistical di culties is unwarranted.
An alternative test, when normality is in doubt, might be to use a Wilcoxon-MannWhitney analogue of the TOST (based on the original logarithmically transformed data for a parallel design, or the intrasubject between-period di erences of the logarithmically transformed data, as proposed by Hauschke, Steinijans and Diletti (1990) , for a crossover design). It has been noted (e.g., Westlake, 1981; Schuirmann, 1981) 
is contained in the interval ( L ; U ). In fact, both FDA (1992) as well as EC-GCP (1993) specify that the TOST should be executed in this fashion. The fact that the TOST seemingly corresponds to a 100(1?2 )%, not 100(1? )%, condence interval procedure initially caused some concern (Westlake 1976 (Westlake , 1981 . Recently, Brown, Casella and Hwang (1995) called this relationship an \algebraic coincidence." But many authors (e.g., Shao, 1990, and Schuirmann, 1989) have de ned bioequivalence tests in terms of 100(1 ? 2 )% con dence sets.
Standard statistical results, such as Theorems 3 and 4 in Section 5, give relationships between size-tests and 100(1 ? )% con dence intervals. In Section 5, we discuss a 100(1 ? )% con dence interval that corresponds exactly to the size-TOST. We also explore the relationship between 100(1 ? 2 )% con dence intervals and size-tests. We describe situations more general than the TOST in which size-tests can be de ned in terms of 100(1 ? 2 )% con dence intervals. But we also give examples from the bioequivalence literature of tests that have been de ned in terms of 100(1? 2 )% con dence intervals and sets that are not size-tests. Tests de ned by 100(1 ? 2 )% con dence intervals can be either liberal or conservative. Because of these potential di culties, our conclusion is that the practice of de ning bioequivalence tests in terms of 100(1 ? 2 )% con dence intervals should be abandoned. If both a con dence interval and a test are required, a 100(1 ? )% con dence interval that corresponds to the given size-test should be used.
Multiparameter problems
In Section 6, we discuss multiparameter bioequivalence problems. We discuss two examples in which the IUT theory can be used to de ne size-tests that are uniformly more powerful than tests that have been previously proposed. These examples concern controlling the experimentwise error rate when several parameters are tested for equivalence, simultaneously.
3 Intersection-Union Tests Berger (1982) proposed the use of intersection-union tests in a quality control context closely related to bioequivalence testing. Tests for many di erent bioequivalence hypotheses are easily constructed using the IUT method. The TOST is a simple example of an IUT. Tests with a speci ed size are easily constructed using this method, even in complicated problems involving several parameters. And tests that are uniformly more powerful than standard tests can often be constructed using this method.
The IUT method is useful for the following type of hypothesis testing problem. Let denote the unknown parameter ( can be vector valued) in the distribution of the data X.
Let denote the parameter space. Let 1 ; : : :; k denote subsets of . Suppose we wish to test
where A c denotes the complement of the set A. The important feature in this formulation is the null hypothesis is expressed as a union and the alternative hypothesis is expressed as an intersection. For i = 1; : : :; k, let R i denote a rejection region for a test of H 0i : 2 i versus H ai : 2 c i . Then an IUT of (9) An important feature in Theorem 1 is that each of the individual tests is performed at level-. But the overall test also has the same level . There is no need for multiplicity adjustment for performing multiple tests. The reason there is no need for such a correction is the special way the individual tests are combined. H 0 is rejected only if every one of the individual hypotheses, H 0i , is rejected.
Theorem 1 asserts that the IUT is level-. That is, its size is at most . In fact, a test constructed by the IUT method can be quite conservative. Its size can be much less that the speci ed value . But, Theorem 2 (a generalization of Theorem 2 in Berger (1982) ) provides conditions under which the IUT is not conservative; its size is exactly equal to the speci ed .
Theorem 2 For some i = 1; : : :; k, suppose R i is a size-rejection region for testing H 0i versus H ai . For every j = 1; : : :; k; j 6 = i, suppose R j is a level-rejection region for testing H 0j versus H aj . Suppose there exists a sequence of parameter points l ; l = 1; 2; : : :, in i such that lim l!1 P l (X 2 R i ) = : and, for every j = 1; : : :; k; j 6 = i, Note that in Theorem 2, the one test de ned by R i has size exactly . The other tests de ned by R j ; j = 1; : : :; k; j 6 = i, are level-tests. That is, their sizes may be less than . The conclusion is the IUT has size . Thus, if rejection regions R 1 ; : : :; R k with sizes 1 ; : : :; k are combined in an IUT and Theorem 2 is applicable, then the IUT will have size equal to max i f i g. We will discuss bioequivalence examples in which tests of di erent sizes are combined. The resulting test has size equal to the maximum of the individual sizes. (2).
To use Theorem 2 to see that the size of the TOST is exactly , consider parameter points with T ? R = U and take the limit as 2 D ! 0. Such parameters are on the boundary of H 02 . Therefore, P(X 2 R 2 ) = P(T U ?t ;r ) = ;
for any 2 D > 0. But, P(X 2 R 1 ) = P(T L t ;r ) ! 1; as 2 D ! 0; because the power of a one-sided t test converges to one as 2 D ! 0 for any point in the alternative. The value T ? R = U is in the alternative, H a1 .
The advantage of considering bioequivalence problems in an IUT format is not limited to verifying properties of the TOST. Rather, other bioequivalence hypotheses, such as (1), state an interval as the alternative hypothesis. This interval can be expressed as the intersection of two one-sided intervals. So two one-sided, size-tests can be combined to obtain a level-(typically, size-) test. Furthermore, as we will see in Section 6, even more complicated forms of bioequivalence can be expressed in the IUT format. This allows the easy construction of tests with guaranteed size-for these problems.
More powerful tests
Despite its simplicity and intuitive appeal, the TOST su ers from a lack of power. The line labeled TOST in the top part of Table 1 shows the power function, P(reject H 0 ), for parameter points with T ? R = U (or L ), points on the boundary between H 0 and H a .
The power function is near for 2 D near 0, but decreases as 2 D grows. An unbiased test would have power equal to for all such parameter points. The TOST is clearly biased. The bottom part of Table 1 shows the power function when the two drugs are exactly equal, T = R . The power is near one for 2 D near zero, but decreases to zero as 2 D increases. Despite these shortcomings, Diletti, Hauschke and Steinijans (1991) declared that the TOST maximizes the power among all size-tests. This is incorrect. Anderson and Hauck (1983) Patel and Gupta (1984) and Rocke (1984) proposed the same test. This scienti c coincidence was commented upon by Anderson and Hauck (1985) and Martin Andr es (1990) . Due to the seriousness of a Type I error, declaring two drugs to be equivalent when they are not, the search for a size-test that was uniformly more powerful than the TOST continued. Munk (1993) proposed a slightly di erent test. Munk claims that this test is a size-test that is uniformly more powerful than the TOST. But this claim is supported by numerical calculations, not analytic results. Brown, Hwang and Munk (1995) constructed an unbiased, size-test of (2) that is uniformly more powerful than the TOST. Their construction is recursive. To determine if a point (d; se(D)) is in the rejection region of the Brown, Hwang and Munk test, a good deal of computing can be necessary. This may limit the practical usefulness of the Brown, Hwang and Munk test. Also, sometimes the Brown, Hwang and Munk rejection region has a quite irregular shape. An example of this is shown in Figure 1 .
We will now describe a new test of the hypotheses (2). This test is uniformly more powerful than the TOST. ?(k ? 1 2 ) ?(k) ; if r is even. The probability density function of V will be denoted by g D (v).
We will describe the rejection region of the new test geometrically here. Exact formulas are in the Appendix. The new test will be an IUT. We will de ne a size-, unbiased rejection region, R 2 , for testing (6). This R 2 will contain the rejection region of the size-TOST and will be approximately symmetric about the line d = 0. Then we will de ne R 1 = f(d; s ) : (?d; s ) 2 R 2 g. R 1 is R 2 re ected across the line d = 0. R 1 is a size-, unbiased rejection region for testing (5). Then R = R 1 \R 2 is the rejection region of the new test. Because R 2 is approximately symmetric about the line d = 0, R 1 is almost the same as R 2 , and not much is deleted when we take the intersection. This foresight in choosing the individual rejection regions so that the intersection is not much smaller is always useful when using the IUT method.
The set fV = vg is a semicircle in (d; s ) space. For each value of v, R 2 (v) fV = vg\R 2 is either one or two intervals of b values, that is, one or two arcs on fV = vg. These arcs will be chosen so that, for every v > 0,
(10)
Then the rejection probability
for every D > 0 if T ? R = . This will ensure that R 2 is a size-, unbiased rejection region for testing (6).
We now de ne the arc(s) that make up R 2 (v). Refer to Figure 2 in this description. The rejection region of the size-TOST, call it R T , is the triangle bounded by the lines s = 0, d = ?t ;r s = p r (call this line l U ), and d = ? +t ;r s = p r (call this line l L ). Let v 0 denote the distance from ( ; 0) to l L . In this description, we assume 1=2 > > 1 ?F(3 =4). Brown, Hwang and Munk (1995) The cross-sections R 2 (v) have been de ned for every v > 0, and this de nes R 2 . R 1 is the re ection of R 2 across the s axis, and the rejection region of the new test is R = R 1 \R 2 .
This construction is illustrated in Figure 3 .
In Figure 1, suggested that such procedures should be truncated in the sense that the narrowest point of the rejection region be determined and then the rejection region is extended along the s axis only of this width. Brown, Hwang and Munk suggest this as a possible modi cation of their test, although the resulting test will no longer be unbiased. We believe that notions of size, power, and unbiasedness are more fundamental than \intuition" and do not recommend truncation. But for those who disagree, our new test could be truncated in this same way. The narrowest point will need to be determined numerically for all these tests, and the smoother shape of our rejection region will make this determination easier. Referring to Figure 1 , a numerical routine might be fooled by the irregular shape of the Brown, Hwang and Munk test.
Tests for ratios of parameters
Usually, data from a bioequivalence trial is logarithmically transformed before analysis. This leads to a test of the hypotheses (2), as described in the previous section. In the model we will consider now, the original data are normally distributed. Let X 1 ; : : :; X m form a random sample from a normal population with mean T and variance 2 , and Y 1 ; : : :; Y n form an independent random sample from a normal population with mean R and variance 2 . In this section, we will present our comments in terms of this simple parallel design. Yang (1991) and Liu and Weng (1995) describe models for this normally distributed data in crossover experiments.
The bioequivalence hypothesis to be tested in this case is (1), namely, The testing problem (14) was rst considered by Sasabuchi (1980 Sasabuchi ( , 1988a . Let X, Y , and S 2 denote the two sample means and the pooled estimate of 2 . Sasabuchi showed that the size-likelihood ratio test of (14) Yang (1991) and Liu and Weng (1995) proposed tests closely related to the T 1 =T 2 test for the bioequivalence problem of testing (13) in a crossover experiment. Hauck and Anderson (1992) also discuss the hypotheses in the form (14). But no reference to Sasabuchi's earlier work is given. The derivation of the con dence set for T = R in Hsu, Hwang, Liu, and Ruberg (1994) contains a mistake in the standardization. Properly corrected, their rather complicated con dence set would lead to the rejection of (14) when the simple test described above does. So, somehow, the value of this simple, size-test seems to have been completely overlooked in the bioequivalence literature. Rather, and Liu and Weng (1995) Theorem 2 can be used to show that, as a test of the hypothesis (13), the T 1 =T 2 test has size 2 > . It is a liberal test. The true size of the T 1 =T 2 test, for a nominal size of = :05, is shown in Table 2 . In Table 2 it is assumed that the sample sizes from the test and reference drugs are equal, m = n. In this case, the size of the T 1 =T 2 test is simply 2 = P T < ?
where T has a students t distribution with r = 2n ? 2 degrees of freedom. It can be seen that the size of the T 1 =T 2 test is about .07 for all sample sizes. The liberality worsens slightly as the sample size increases.
On the other hand, the T 1 =T 2 test has size exactly equal to the nominal . It is just as simple to implement as the T 1 =T 2 test. Therefore the T 1 =T 2 test should replace the T 1 =T 2 test for testing (13). In Section 4.2, the IUT method was used to construct a size-test that is uniformly more powerful than the TOST. For the known 2 case, Berger (1989) and Liu and Berger (1995) used the IUT method to construct size-tests that are uniformly more powerful than the T 1 =T 2 test. In Figure 4 , the cone shaped region labeled R o is the rejection region of the T 1 =T 2 test for = :05. The region between the dashed lines is the rejection region of Liu and Berger's size-test that is uniformly more powerful. We refer the reader to Berger (1989) and Liu and Berger (1995) for the details about these tests. We believe that for the 2 unknown case, size-tests that are uniformly more powerful than the T 1 =T 2 test will be found. The con dence interval (16) has been derived by Hsu (1984 ), Bo nger (1985 , and Stefansson, Kim, and Hsu (1988) in the multiple comparisons setting, and by M uller-Cohrs (1991), Bo nger (1992), and Hsu, Hwang, Liu, and Ruberg (1994) in the bioequivalence setting. Our derivation follows Stefansson, Kim, and Hsu (1988) and Hsu, Hwang, Liu, and Ruberg (1994) , which makes the correspondence to TOST more explicit.
To see this correspondence, we use the standard connection between tests and con dence sets. Most often in statistics, this connection is used to construct con dence sets from tests via a result such as the following.
Theorem 3 (Lehmann, 1986, p. 90) Let the data X have a probability distribution that depends on a parameter . Let denote the parameter space. For each 0 2 , let A( 0 ) denote the acceptance region of a level-test of H 0 : = 0 . That is, for each 0 2 , P = 0 (X 2 A( 0 )) 1 ? : Then, C(x) = f 2 : x 2 A( )g is a level 100(1 ? )% con dence set for .
But in bioequivalence testing in the past, tests have often been constructed from condence sets. A result related to this practice follows. Theorem 4 Let the data X have a probability distribution that depends on a parameter . Suppose C(X) is a 100(1 ? )% con dence set for . That is, for each 2 , P ( 2 C(X)) 1 ? . Proof. Let 0 2 0 . Then P 0 (reject H 0 ) 1 ? P 0 ( 0 2 C(X)) :
Unfortunately, Theorem 4 has not always been carefully applied in the bioequivalence area. Commonly, 100(1 ? 2 )% con dence sets are used in an attempt to de ne leveltests. Theorem 4 guarantees only that a level-2 test will result from a 100(1 ? 2 )% con dence set. Sometimes, the size of the resulting test is, in fact, , but this is not generally true. In this subsection we use Theorem 3 to show the correspondence between the 100(1 ? )% con dence interval (16) and the size-TOST. In the next subsection, we criticize the practice of using 100(1 ? 2 )% con dence sets to de ne bioequivalence tests. (17) leads to usual equivariant con dence interval, which is of the form (8) but with t ;r replaced by t =2;r .
However, no current law or regulation states one must employ con dence sets that are equivariant over the entire real line. Using Theorem 3 and inverting the family of size- yields the 100(1 ? )% con dence interval (16). Technically, when inverting (18) and (19), the upper con dence limit will be open when D+t ;r SE(D) < 0. This point is inconsequential in bioequivalence testing. The only value of the upper bound with positive probability is 0, and, in bioequivalence testing, the inference T 6 = R is not of interest. In terms of operating characteristics, the con dence interval with the possibly open endpoint has coverage probability 100(1 ? )% everywhere. The con dence interval (16) also has coverage probability 100(1 ? )% except at T ? R = 0 where it has 100% coverage probability. Note that the family of tests (18) contains the one-sided size-t-test for (6), and the family of tests (19) Stefansson, Kim, and Hsu (1988) , gives rise to the multiple comparison with the best (MCB) con dence intervals of Hsu (1984) , which eliminate treatments that are not the best and identify treatments close to the true best. In fact, the bioequivalence con dence interval (16) is an MCB con dence interval because, when only two treatments are being compared, a treatment close to the other treatment is either the true best treatment or close to the true best treatment.
This ability of MCB con dence interval to give practical equivalence inference is useful in another problem. Ruberg and Hsu (1992) pointed out that whether to include certain parameters in a regression model should sometimes be formulated as a practical equivalence problem rather than a signi cant di erence problem. In modeling the stability of a drug, for example, given the clear intent of the FDA (1987) Guideline that data from batches of a drug can be pooled only if they have practically equivalent degradation rates, the decision of which time batch interaction terms to include in the model can logically be based on MCB con dence intervals comparing the degradation rate of each batch with the true worst degradation rate. Another problem which has not been but should be formulated as one of practical equivalence is the establishment of safety of substances such as bovine growth hormone in toxicity studies (e.g., Juskevich and Guyer, 1990) , since the desired inference is practical equivalence between the treated groups and the (negative) control group (cf. Hsu, 1996, Chapter 2).
A di erent multiparameter extension of the same construction was utilized by Brown, Casella, and Hwang (1995) to obtain the con dence region for a vector parameter which has the smallest expected volume when = 0, generalizing Pratt's result. The con dence set is constructed through Theorem 3 using the family of size-Neyman 
Their paper describes and illustrates interesting geometric properties of C(^ ):
It should be pointed out that the utility of Theorem 3 is not restricted to the construction of con dence sets which give better practical equivalence inference. Stefansson, Kim, and Hsu (1988) and Hayter and Hsu (1994) used Theorem 3 to construct con dence sets associated with step-down and step-up multiple comparison methods, which are usually thought of as speci cally constructed to give better signi cant di erence inference than single-step methods.
5.2 100(1 ? 2 )% con dence intervals Bioequivalence tests are often de ned in terms of 100(1 ? 2 )% con dence sets. That is, if denotes the parameter of interest, c 0 denotes the set of parameter values for which the drugs are bioequivalent, and C(X) is a 100(1 ? 2 )% con dence set for , then the drugs are declared bioequivalent if and only if C(X) c 0 . This practice seems to be based entirely on the perceived equivalence between the 100(1? 2 )% con dence interval (8) and the size-TOST of (2). This practice is encouraged by the fact that both FDA (1992) and EC-GCP (1993) specify that the = :05 TOST should be executed by constructing a 90% con dence interval. In the bioequivalence literature, when used in this way, the 90% is called the assurance of the con dence set.
The intent of the regulating agencies is clearly to use a test with size = :05. Unfortunately, bioequivalence tests have been proposed using 100(1 ? 2 )% con dence sets without any veri cation that the resulting tests have size-. Theorem 4 guarantees that the resulting test is a level-2 test, not size-. In this section, we will explore the usage of 100(1 ? 2 )% con dence sets. We shall show that the usual 100(1 ? 2 )% con dence interval (8) results in a size-TOST of (2) because (8) is \equal-tailed." So the relationship is deeper than the \algebraic coincidence" mentioned by Brown, Casella and Hwang (1995) . Hauck and Anderson (1992) discuss this fact without proof. But we shall see in examples that the use of 100(1 ? 2 )% con dence sets can result in both liberal and conservative bioequivalence tests. Because there is no general guarantee that a 100(1? 2 )% con dence set will result in a size-test, we believe it is unwise to attempt to de ne a size-test in terms of a 100(1 ? 2 )% con dence set. Rather, a test with the speci ed Type I error probability of should be used. Theorem 3 might be used to construct the corresponding 100(1 ? )% con dence set.
Let C ? ; C + ] denote (8), the usual 100(1 ? 2 )% con dence interval for T ? R . Why does rejecting H 0 in (2) if and only if C ? ; C + ] ( L ; U ) result in a size-test? The super cial answer is that, obviously, C + < U is equivalent to T U < ?t ;r and C ? > L is equivalent to T L > t ;r . Thus, the test based on C ? ; C + ] is equivalent to the size-TOST.
But a more thorough understanding of this is suggested by the following result (Exercise 9.1, Casella and Berger, 1990) .
Theorem 5 Let the data X have a probability distribution that depends on a real-valued parameter . Suppose (?1; U(X)] is a 100(1? 1 )% upper con dence bound for . Suppose L(X); 1) is a 100(1 ? 2 )% lower con dence bound for . Then, L(X); U(X)] is a 100(1 ? 1 ? 2 )% con dence interval for . Now consider the 100(1 ? 2 )% con dence interval C ? ; C + ] for = T ? R . The interval (?1; C + ] is a 100(1 ? )% upper con dence bound for . From Theorem 4, the test that rejects H 02 in (6) if and only if C + < U is a level-test of H 02 . Likewise, C ? ; 1) is a 100(1 ? )% lower con dence bound for and the test that rejects H 01 in (5) if and only if C ? > L is a level-test of H 01 . Forming an IUT from these two level-tests yields a level-test of H 0 in (2), by Theorem 1. Thus, we see that it is not so important that C ? ; C + ] is a 100(1 ? 2 )% con dence interval for . Rather, it is the fact that (?1; C + ] and C ? ; 1) are both 100(1 ? )% con dence intervals that yields a level-test. That is, it is important that C ? ; C + ] is an \equal-tailed" con dence interval.
It is easy to see that 100(1?2 )% con dence intervals will not always yield size-tests.
Consider an \unequal-tailed" 100(1 ? 2 )% con dence interval for = T ? R Yee (1986) . The size of this test can be made arbitrarily close to 2 by choosing 1 close to zero and 2 close to 2 . In this problem, the only 100(1 ?2 )% con dence interval of the form (21) that de nes a size-test happens to be the usual, equal-tailed con dence interval, C ? ; C + ].
The preceding example using an unequal-tailed test simply illustrates that de ning a bioequivalence test in terms of a 100(1 ? 2 )% con dence interval can lead to a liberal test with size greater than . But, no one has proposed using the interval (21) to de ne a bioequivalence test. So we now discuss two other examples that have been proposed in the bioequivalence literature. Both examples concern testing (1) about the ratio T = R .
Tests based on 100(1 ? 2 )% Fieller-type con dence intervals provide examples of tests that are sometimes liberal. Mandallaz and Mau (1981) , Locke (1984) and Kinsella (1989) all propose using a Fieller-type (1940 Fieller-type ( , 1954 con dence interval to estimate T = R . Neither
Locke nor Kinsella propose constructing a bioequivalence test using this interval. But Mandallaz and Mau (1981) , Yee (1986 Yee ( ,1990 , Metzler (1991) and Schuirmann (1989) all propose de ning a test of (1) using these Fieller con dence intervals, and all suggest that a 100(1?2 )% con dence interval should be used. A test de ned in this way using the Locke 100(1?2 )% con dence interval is, in fact, a size-tests because the Locke interval is equaltailed. But, Metzler (1991) and Schuirmann (1989) give graphs of the power function of the Mandallaz and Mau (1981) test that show that the test has size greater than the speci ed . For example, Figures 3 through 9 in Metzler (1991) are graphs of 1 ? (power function) based on the Mandallaz and Mau (1981) con dence interval. At U = 1:2, the rejection probability is about :07 for the = :05 test, and, the power is about :15 for the = :10 test.
These gures cover a variety of sample sizes and variances. But in all cases the rejection probability exceeds the nominal at U = 1:2. The same liberality of the Mandallaz and Mau test is illustrated by Figures 3{13 of Schuirmann (1989) .
On the other hand, a test de ned in terms of a 100(1 ? 2 )% con dence set might be very conservative. An example is the test proposed by Chow and Shao (1990) for testing
(1) about the ratio T = R . Speci cally, Chow and Shao considered a two period crossover design with no carry-over, period or sequence e ects. Let X denote the sample mean vector with mean = ( T ; R ) 0 and let S denote the sum of cross-products matrix. Let m patients receive the rst sequence, n patients receive the second sequence and n = n + m. Then, C = f : T 1 F ;2;n ?2 g de nes a 100(1 ? )% con dence ellipse for , where T 1 = n (n ? 2)(X ? ) 0 S ?1 (X ? )=2 and F ;2;n ?2 is the upper 100 percentile of an F-distribution with 2 and n ? 2 degrees of freedom. Chow and Shao propose rejecting H 0 in (1) and concluding H a : L < T = R < U is true if and only if the 90% con dence ellipse is contained in the cone de ned by H a . They do not comment on the actual size of this test, but we assume 90% was chosen to be 100(1 ? 2 )% where = :05.
Chow and Shao's test can be described much more simply by recalling the relationship between the con dence ellipse, C, and simultaneous con dence intervals for all linear functions l 0 (Sche e, 1959) Theorems 1 and 2 then tell us that the actual size of this test is 0 = P(T > p 2F ;2;n ?2 ), where T has a Student's t distribution with n ? 1 degrees of freedom. This is because T L has this t-distribution if l 0 L = 0, and T U has this t-distribution if l 0 U = 0. That is, 0 is the size of each of the two individual tests. We computed 0 using a 90% con dence ellipse as suggested by Chow and Shao. We found that 0 = :017 for m = n = 5, 10, and 15, and 0 = :016 for m = n = 20, 30, and 1. Thus, if the intent of using a 100(1 ? 2 )% = 90% con dence ellipse was to produce a bioequivalence test with type I error probability of = :05, the result was very conservative. This practice produces tests with the appropriate size only when special, \equal-tailed" con dence intervals are used, and o ers no intuitive insight. The mixture of 100(1 ? 2 )% con dence sets and size-tests is only confusing. Rather, a test with the speci ed Type I error probability of should be used. The IUT method can usually be used to construct such a test. Then, Theorem 3 might be used to construct the corresponding 100(1 ? )% con dence set.
Multiparameter Equivalence Problems
Until now, we have discussed bioequivalence testing in terms of only one parameter. In this section, we discuss two problems in which the desired inference is equivalence in terms of two parameters. These results immediately generalize to situations in which bioequivalence is de ned in terms of more than two parameters. These two examples have been discussed as multiparameter bioequivalence problems by several authors. But, in some cases, the tests that have been proposed do not have the correct size . The proposed tests do not properly account for the multiple testing aspect of this problem. These two multiparameter examples vividly illustrate that the IUT method can provide a simple mechanism for constructing tests with the correct size , even in seemingly complicated bioequivalence problems. Size-tests can be combined to obtain an overall size-test. No adjustment for multiple testing is needed if the IUT method is used.
Simultaneous AUC and C max bioequivalence
Sections 4 and 5 discussed bioequivalence testing in terms of only one parameter. That is, the test and reference drugs are to be compared with respect to either average AUC or average C max . FDA (1992) and EC-GCP (1993) consider two drugs are bioequivalent only if they are similar in both parameters. Westlake (1988) and Hauck et al. (1995) have considered the problem of comparing AUC and C max simultaneously. (Westlake actually compares three parameters, including T max also. But this does not conform to current FDA guidelines.)
Assume the measurements are lognormal so that, after log transformation, we wish to consider hypotheses like (2). Let the superscripts A and C refer to the variables AUC and C max , respectively. For example, C R denotes the mean of log(C max ) for the reference drug. The test and reference drugs are to be considered bioequivalent only if H m a : Therefore, to test H m 0 versus H m a , Westlake's procedure can be used except that each of the two TOSTs should be performed at size-. The resulting test has probability at most of declaring the drugs to be bioequivalent, if they are bioinequivalent. Hauck et al. (1995) propose testing (23) using two size-TOSTs. They recognize that the Bonferroni adjustment recommended by Westlake is unnecessary. But they come to the opposite conclusion. Based on a simulation study, they conclude that this test is too conservative and suggest that the two TOSTs might be performed using a higher error rate than , and the resulting test of (23) would be size-. (They admit that more simulations are needed to con rm this conjecture.) But, if the two TOSTs are each size-, then the test of (23) T ? C R , respectively. In this limit, three of the four one-sided tests will have rejection probability converging to 1, because these parameter points are in the alternative hypothesis and the corresponding standard deviations are converging to 0. The forth onesided test will have rejection probability exactly equal to , for all such parameter points, because L = A T ? A R is on the boundary. A test that is uniformly more powerful, but still has size-will be obtained if the test we propose in Section 4.2 is used to perform the two tests, rather than using the two TOSTs. Again, both of these tests would be performed at size-.
An alternative way of assessing the simultaneous bioequivalence of AUC and C max is to inspect the Brown, Casella, and Hwang (1995) which leads to the con dence region C(^ ;^ ) = : 0^ = q 0^ =n + t ;n?1 > 0 = q 0^ =n :
(24) Brown, Casella, and Hwang (1995) applied (20) to the simultaneous AUC and C max problem for illustration, assuming is known. In practice, this assumption is perhaps unrealistic considering the moderate sample size typical in bioequivalence trials.
6.2 Mean and variance bioequivalence Anderson and Hauck (1990) and Liu and Chow (1992) 
The constants L , U , L , and U would be chosen to de ne clinically important di erences. Liu and Chow (1992) Liu and Chow note that the test statistics use for the TOST are independent of the test statistics used in their test. But they give no further explanation of (26). The probability that H 0 is accepted, given that H 0 is true, is bounded below by 1 ? 1 . The probability that H 0 is accepted, given that H 0 is true, is bounded below by 1 ? 2 . So the quantity in (26) is an upper bound for the probability that at least one of the two tests rejects its null hypothesis, given that both H 0 and H 0 are true. This is not the error probability of the proposed test. The error probability is the probability the both tests reject, given that either H 0 or H 0 is true. H m 0 is the union of H 0 and H 0 , not the intersection.
Again, it should be noted that a more powerful size-test of H m 0 will be obtained if the test from Section 4.2, rather than the TOST, is used to test H 0 and Wang's (1994) test is used to test H 0 .
Concluding Remarks
We have shown that the theory of intersection-union tests is central to bioequivalence studies. We have demonstrated the danger of incorrect association of con dence sets with such tests. Due to the traditional emphasis on signi cant di erence inference in statistics, many practical equivalence problems have not been recognized as such, we believe. It is our hope (and anticipation) that the concepts and techniques discussed in this article will, in time, prove to be useful not only in bioequivalence studies, but in other practical equivalence problems as well.
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A Details of New Test in Section 4.2 A size-, nearly unbiased test for (2) was described geometrically in Section 4.2. In Section A.1, formulas and computational suggestions are given for the quantities that de ne that test. The construction in Section 4.2 is valid for > . In Section A.2 a similar construction yields a size-, nearly unbiased test for . Brown, Hwang and Munk did not propose any test for . 
A.2 New test for
For small values of , a size-, nearly unbiased test of (2), that is uniformly more powerful than the TOST, can be constructed. The construction is very similar, and somewhat simpler, than the construction in Section 4.2. The notation of Section A.1 will be used, and Figure 5 Figure 5 , R 2 is outlined with a solid line, R 1 is outlined with a dashed line, and the intersection is the rejection region of the IUT.
